RxDoctor Payments Data

Christopher Vare, MD

Family Medicine · Columbus, NJNPI 1558688986

Payments from drug & device makers

$4,861in general payments, 2019–2025

Across 354 payments — averaging $13.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$592
  • Novo Nordisk$580
  • Axsome Therapeutics, Inc.$275
  • Astellas Pharma US Inc$174
  • Sanofi-aventis U.S. LLC$170
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$4,861100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,861 in reported general payments places this provider in the 85th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$118,183
Medicare patients
297
Services billed
1,580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide49$99,093
EliquisApixaban102$92,401
JanuviaSitagliptin Phosphate75$79,273
FarxigaDapagliflozin Propanediol61$68,069
TrulicityDulaglutide33$56,957
OzempicSemaglutide40$49,311
MounjaroTirzepatide35$49,113
OxycontinOxycodone Hcl12$42,106
JardianceEmpagliflozin22$38,321
Breo ElliptaFluticasone/Vilanterol40$25,101
LinzessLinaclotide19$23,653
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog23$23,469
RexultiBrexpiprazole12$16,327
MyrbetriqMirabegron18$13,119
Icosapent Ethyl14$9,434

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$580$148,40489 claims
Lilly USA, LLCTrulicity, Mounjaro$592$106,07068 claims
PfizerEliquis, Paxlovid$87$95,259114 claims
MerckJanuvia, Belsomra$108$86,60392 claims
AstraZenecaFarxiga$50$68,06961 claims
Boehringer IngelheimJardiance$42$38,32122 claims
AbbVieLinzess, Synthroid$1,555$26,25372 claims
GSKBreo Ellipta$55$25,10140 claims
Otsuka America Pharmaceutical, Inc.Rexulti$71$16,32712 claims
Astellas Pharma US IncMyrbetriq$174$13,11918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Columbus

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →